Biblio
Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. Stem Cell Res Ther. 2023;14(1):287.
. Correction: Human adipose-derived mesenchymal stem cells for acute and sub-acute TBI. PLoS One. 2021;16(12):e0261599.
.